Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Dupixent also demonstrated superiority over ... GlobalData is the parent company of Pharmaceutical Technology. Despite the commercial success, tensions between Regeneron and Sanofi have escalated.

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

The FDA approval is still pending, creating uncertainty around the market acceptance and commercial success of Dupixent for treating bullous pemphigoid, which may affect investor confidence.

including without limitation Dupixent ® (dupilumab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

including without limitation Dupixent® (dupilumab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...